Thursday, September 10, 2015 6:58:18 PM
"The outstanding principal and accrued interest of each Secured Convertible Note is convertible, subject to a 4.99% Beneficial Ownership Cap (as defined in the Secured Convertible Notes), into shares of the Company's common stock ("Common Stock") at an initial conversion price of $5.00 per share (subject to adjustment), at the option of the respective holders."
I don't know, that sounds like an expectation of $5 per common share by August 31st 2016 to me.
You know, actually now it seems we have a lot to look forward to over the next year since BK is no longer an option for ATRN. They have already filed in the last few of years and can't do so again for a few more years to come.
(You can only file for BK once every seven years or longer)
Too, consider this, regardless of ATRN's need to borrow cash to stay afloat in the now, this also infers that they will be generating some kind of revenue (one way or another) over the next year in order to not only stay afloat, but to also generate enough cash flow to pay their creditors back as well.
Recent PTIX News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:29:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 08:50:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 10:18:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:02:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/02/2023 08:29:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/13/2023 04:48:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:29:32 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM